This has been achieved by completing the acquisition of the remaining
52% of Alcon shares owned by Nestlé for a total of USD 28.3 billion.
Alcon strategically complements Novartis' business portfolio, adding a
world class growth platform in eye care to its Pharmaceutical,
Generics, Vaccines and Diagnostics and Consumer Health Divisions,
building an even stronger leadership position in healthcare. Alcon is
the world's largest and most profitable eye care company with 2009
annual sales of USD 6.5 billion, operating income of USD 2.3 billion
and net income of USD 2.0 billion.
The eye care sector offers further growth opportunities underpinned by
the increasing unmet needs of emerging markets and an aging population.
The Alcon and Novartis eye care portfolios address a broad range of
these unmet needs.
"We are delighted to become majority owners of Alcon. Together, both
companies can achieve their strategic priorities to deliver against
patient needs through innovative and differentiated products" said
Joseph Jimenez, CEO of Novartis.
Novartis and Nestlé entered into an agreement in April 2008 for the sale of Nestlé's 77% majority stake in Alcon to Novartis in two steps. The total cost to Novartis for the 77% majority stake of Alcon is USD 38.7 billion (USD 168 per share). In July 2008, Novartis acquired in a first step a 25% stake in Alcon for USD 10.4 billion and the additional 52% stake has been acquired for USD 28.3 billion.
